Cantor Fitzgerald Comments on Prothena FY2025 Earnings

Prothena Co. plc (NASDAQ:PRTA) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Prothena in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipates that the biotechnology company will post earnings per share of ($3.97) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Prothena’s current full-year earnings is ($2.24) per share.

Other analysts also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $48.00 price objective (down previously from $84.00) on shares of Prothena in a research note on Friday, December 20th. StockNews.com downgraded shares of Prothena from a “hold” rating to a “sell” rating in a research note on Tuesday, November 19th. Chardan Capital started coverage on shares of Prothena in a report on Friday, December 20th. They set a “buy” rating and a $40.00 price objective for the company. Finally, Bank of America dropped their target price on shares of Prothena from $26.00 to $22.00 and set a “neutral” rating on the stock in a research note on Thursday, December 19th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $46.50.

Prothena Trading Up 2.5 %

Shares of Prothena stock opened at $14.11 on Wednesday. The stock has a 50 day moving average price of $14.35 and a 200-day moving average price of $18.04. Prothena has a one year low of $11.70 and a one year high of $34.75.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) EPS for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.08. Prothena had a negative net margin of 98.86% and a negative return on equity of 24.19%. The firm had revenue of $0.97 million during the quarter, compared to the consensus estimate of $1.22 million. During the same quarter last year, the firm earned $0.38 EPS. The firm’s revenue for the quarter was down 98.9% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. increased its holdings in Prothena by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,344 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 4,026 shares during the period. Intech Investment Management LLC purchased a new position in shares of Prothena in the 3rd quarter valued at $210,000. XTX Topco Ltd purchased a new position in shares of Prothena in the 3rd quarter valued at $260,000. Orion Portfolio Solutions LLC raised its position in shares of Prothena by 4.4% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 17,531 shares of the biotechnology company’s stock worth $293,000 after acquiring an additional 739 shares in the last quarter. Finally, Creative Planning bought a new stake in Prothena during the third quarter valued at about $350,000. Hedge funds and other institutional investors own 97.08% of the company’s stock.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.